A biomaterial that can mimic certain behaviors within biological tissues could advance regenerative medicine, disease modeling, soft robotics and more, according to researchers.

A biomaterial that can mimic certain behaviors within biological tissues could advance regenerative medicine, disease modeling, soft robotics and more, according to researchers at Penn State.

Topical ABT-263 effectively reduced several senescence markers in aged skin, preparing it for improved wound healing.

Collagen, the body's most abundant protein, has long been viewed as a predictable structural component of tissues. However, a new study challenges that notion, revealing an unexpected confirmation in ...

The OHSU Center for Regenerative Medicine investigates the use of cell therapeutics and novel biomaterials for the treatment of diseases and injuries. Focusing on translational research, researchers ...

In this manuscript the authors established a novel three-dimensional culture system for stratified epithelia that allows epithelial cells to undergo epithelial-to-mesenchymal transition (EMT) and ...

Doctors and their patients discuss the range of services that Duke Cancer Institute provides to teens and younger adults with a history of cancer. Beyond Cancer: Mental Health and Therapy Duke ...

Duke clinicians and patients discuss how approaches such as talk, music, and art therapy can address psychosocial issues that cancer survivors often face. Beyond Cancer: Building Bridges Experts ...

Items not to scale. Photographed at Emperor’s College of Traditional Oriental Medicine, Santa Monica, California and National Wildlife Property Repository, Commerce City, Colorado. This 1620 ...

Highlights,Vericel expands regenerative medicine impact.,Institutional investors increase stakes in Vericel.,Innovative ...

Medical research involves research in a wide range of fields, such as biology, chemistry, pharmacology and toxicology with the goal of developing new medicines or medical procedures or improving ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...